Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))

on behalf of the RELIVE Investigators

doi:10.1016/S2468-1253(19)30152-9

Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))

on behalf of the RELIVE Investigators

Research output: Contribution to journal › Comment/debate › peer-review

Abstract

Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.

Original language	English (US)
Pages (from-to)	e6
Journal	The Lancet Gastroenterology and Hepatology
Volume	4
Issue number	7
DOIs	https://doi.org/10.1016/S2468-1253(19)30152-9
State	Published - Jul 1 2019

All Science Journal Classification (ASJC) codes

Hepatology
Gastroenterology

Access to Document

10.1016/S2468-1253(19)30152-9

Cite this

@article{7391828f68874061a24400229e884f1a,

title = "Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))",

abstract = "Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.",

author = "{on behalf of the RELIVE Investigators} and Philippe Merle and Blanc, {Jean Frederic} and Phelip, {Jean Marc} and Gilles Pelletier and Bronowicki, {Jean Pierre} and Yann Touchefeu and Georges Pageaux and Ren{\'e} Gerolami and Fran{\c c}ois Habersetzer and Eric Nguyen-Khac and Andrea Casadei-Gardini and Ivan Borbath and Albert Tran and Henning Wege and Saad, {Amr Shafik} and Massimo Colombo and Armand Abergel and Carine Richou and Imam Waked and Yee, {Nelson S.} and Audrey Mol{\'e} and Pierre Attali and Boulicaut, {Julie Le} and B{\'e}rang{\`e}re Vasseur",

note = "Publisher Copyright: {\textcopyright} 2019 Elsevier Ltd",

year = "2019",

month = jul,

day = "1",

doi = "10.1016/S2468-1253(19)30152-9",

language = "English (US)",

volume = "4",

pages = "e6",

journal = "The Lancet Gastroenterology and Hepatology",

issn = "2468-1253",

publisher = "Elsevier Ltd",

number = "7",

}

TY - JOUR

T1 - Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))

AU - on behalf of the RELIVE Investigators

AU - Merle, Philippe

AU - Blanc, Jean Frederic

AU - Phelip, Jean Marc

AU - Pelletier, Gilles

AU - Bronowicki, Jean Pierre

AU - Touchefeu, Yann

AU - Pageaux, Georges

AU - Gerolami, René

AU - Habersetzer, François

AU - Nguyen-Khac, Eric

AU - Casadei-Gardini, Andrea

AU - Borbath, Ivan

AU - Tran, Albert

AU - Wege, Henning

AU - Saad, Amr Shafik

AU - Colombo, Massimo

AU - Abergel, Armand

AU - Richou, Carine

AU - Waked, Imam

AU - Yee, Nelson S.

AU - Molé, Audrey

AU - Attali, Pierre

AU - Boulicaut, Julie Le

AU - Vasseur, Bérangère

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.

AB - Merle P, Blanc J-F, Phelip J-M, et al, on behalf of the RELIVE Investigators. Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial. Lancet Gastroenterol Hepatol 2019; 4: 454–65—The appendix for this Article has been updated. This correction has been made to the online version as of June 3, 2019.

UR - http://www.scopus.com/inward/record.url?scp=85066408919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85066408919&partnerID=8YFLogxK

U2 - 10.1016/S2468-1253(19)30152-9

DO - 10.1016/S2468-1253(19)30152-9

M3 - Comment/debate

C2 - 31169125

AN - SCOPUS:85066408919

SN - 2468-1253

VL - 4

SP - e6

JO - The Lancet Gastroenterology and Hepatology

JF - The Lancet Gastroenterology and Hepatology

IS - 7

ER -

Correction to (The Lancet Gastroenterology & Hepatology (2019) 4(6) (454–465), (S2468125319300408), (10.1016/S2468-1253(19)30040-8))

Abstract

All Science Journal Classification (ASJC) codes

Access to Document

Other files and links

Fingerprint

Cite this